Total disc replacement (TDR) for adjacent segment disease after anterior cervical fusion

Kyoung-Suok Cho

Department of Neurosurgery, Uijeongbu St.Mary's Hospital, The Catholic University of Korea College of Medicine, Korea

[Introduction]



Anterior cervical discectomy and corpectomy for the treatment of cervical spondylosis and cervical disc herniation enjoy favorable rates of fusion and successful clinical outcomes. However, postoperative degenerative changes at adjacent discs may lead to the development of new radiculopathy or myelopathy. In the previous reports, the incidence of symptomatic adjacent segment disease has ranged from 7% to 25%.

The present study was undertaken to investigate the incidence of symptomatic adjacent segment disease after anterior cervical interbody fusion (ACF) and to describe availability for cervical total disc replacement (TDR) for those patients.

Material & methods

Between 1999 and 2015, a total of 275 patients underwent anterior cervical interbody fusion for intervertebral disc herniation and cervical spondylosis. A total of 225 of these patients could be followed up clinically and radiologically for more than 2 years (follow-up rate, 82%). Of these, 138 were men and 87 were women and the average age at operation was 51 years (range, 26 to 75 years). The average length of follow-up was 7.8 years (range, 2 to 16 years). The diagnosis of symptomatic adjacent segment disease was based on the presence of new radiculopathy or myelopathy symptoms referable to an adjacent level, and the presence of a compressive lesion at an adjacent level by magnetic resonance imaging.

Results

Symptomatic adjacent segment disease developed in 37 of 225 patients (16.5%) followed. We performed fusion extension two, fusion plus total disc replacement (TDR) 20 and only TDR 15 patients. All patients were improved after surgery without any complication except two transient hoarseness and one soft tissue swelling

[Conclusion]

The cervical total disc replacement (TDR) is a reasonable treatment option for patients who have had previous surgery in which interbody fusion has been performed and who have developed degeneration of adjacent levels.

CURRICULUM VITAE

Education	
1972. 3 - 1978. 2 :	The Catholic Univ. of Korea, College of Medicine (M.D)
1984. 7 - 1986. 2 :	The Catholic Univ. of Korea, Graduate School (M.A)
1987. 9 - 1990. 8 :	The Catholic Univ. of Korea, Graduate School (Ph.D.)
Postgraduate Trai	ning
1981. 5 - 1982. 2 :	Rotating Internship, Catholic Medical Center, Seoul, KOREA
1982. 3 - 1986. 2 :	Residency in Neurosurgery, St. Mary's Hospital, Seoul, KOREA
Academic and Hospital Experiences	
1992. 3 - 1993. 8:	Visiting Professor, The Miami Project to Cure Paralysis
	Dept. of Neurosurgery, Univ. of Miami, USA.
2000. 3 - present:	Professor, Dept. of Neurosurgery. Uijongbu St. Mary's Hospital, The Catholic
2001. 9 - 2002. 8:	Visiting Professor, The Miami Project to
	Dept of Neurosurgery Univ of Miami USA
2014. 3 - 2014. 5:	Visiting Professor, The Miami Project to Cure Paralysis
	Dept. of Neurosurgery, Univ. of Miami, USA

National Social Activity		
2006. 5 - 2008. 5;	President, Korean Neurotruamatology	
2007 0 2016 0	Society	
2007. 9 - 2010. 9.	Neurosurgery Spine Society	
2007. 9 - present:	Executive Committee member, Korean	
*	Cervical Spine Research Society	
2012. 6 - 2014. 5:	President, Korean Neuropain Society.	
International Social Activity		
International Social Activity		
2008. 7- 2015. 5:	Vice President, Asia-Oceania Neurotrauma	
	Society	
2009. 9 - Present:	Executive Committee member, WFNS	
	Neurotrauma Committee	
2015. 6 - 2017. 6:	President, Asia - Oceania Neurotrauma	
	Society	
2016. 9 –Present:	Board member, International Association of	
	Neurorestoratology (IANR)	
Award		
2008 Cervical Spine Research Society Annual Meeting (USA),		
Best Research Award		

2009 Korean Neurotraumatology Society Annual Meeting, Best Paper Award